The labor market in the Netherlands is under significant strain, and healthcare is one of the sectors most affected. This impacts all of us. Ahead of an upcoming Commission debate on Labor Market Policy in Healthcare in our national parliament (Tweede Kamer) on December 19, we’ve sent a letter to the Minister of Health, Welfare and Sport Fleur Agema, Minister of Social Affairs and Employment Eddy van Hijum, Ministry of health welfare and sport, and the Parliamentary Committee. In this letter, together with our partners, we share key points to address the challenges in the healthcare workforce, drawing on the expertise of our partners at Leiden Bio Science Park:
We welcome all stakeholders to discuss strengthening the healthcare workforce together. Let’s work toward meaningful change.
With thanks to our partners:
Municipality of Leiden, Leiden University, Leiden University of Applied Sciences, mboRijnland, LUMC, TNO, Johnson & Johnson Innovative Medicine, and Bristol Myers Squibb.
We invite all stakeholders to join us in conversation about strengthening the healthcare labor market. Let us work together on sustainable and meaningful change.
With thanks to our partners: Municipality of Leiden, Leiden University, Leiden University of Applied Sciences, mboRijnland, LUMC, TNO, Johnson & Johnson Innovative Medicine, and Bristol Myers Squibb.
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.